Table 2.
Prediction results for kidney disease progression in ADPKD using baseline HtTKV plus principal components of transformed baseline features
| Cross Validation |
1 | 2 | 2 | 4 | 5 | Mean | SD |
|---|---|---|---|---|---|---|---|
| HtTKV + Gabor + GLCM | |||||||
| Accuracy | 0.50 | 0.79 | 0.79 | 0.64 | 0.73 | 0.69 | 0.11 |
| Precision | 0.44 | 0.70 | 0.87 | 0.57 | 0.86 | 0.69 | 0.16 |
| Recall | 0.67 | 1.00 | 0.78 | 0.67 | 0.67 | 0.76 | 0.13 |
| F1 | 0.53 | 0.82 | 0.82 | 0.61 | 0.75 | 0.71 | 0.12 |
| AUC | 0.60 | 0.83 | 0.89 | 0.60 | 0.70 | 0.70 |
ADPKD, autosomal dominant polycystic kidney disease; AUC, area under the curve; GLCM, gray level co-occurrence level; HtTKV, height corrected total kidney volume.
AUC is calculated based on the average receiver operating characteristic (ROC) curve of the 5-fold cross validation models.